PL2683385T3 - 2,4-podstawione pirymidynodiaminy do zastosowania w toczniu krążkowym - Google Patents

2,4-podstawione pirymidynodiaminy do zastosowania w toczniu krążkowym

Info

Publication number: PL2683385T3
Authority: PL; Poland
Prior art keywords: discoid lupus; substituted pyrimidinediamines; pyrimidinediamines; substituted; discoid
Prior art date: 2011-03-10

Application number

PL12711500T

Other languages

English (en)

Inventor

Daniel Magilavy

Polly Pine

Original Assignee

Rigel Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-10

Filing date

2012-03-09

Publication date

2018-12-31

2012-03-09 Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.

2018-12-31 Publication of PL2683385T3 publication Critical patent/PL2683385T3/pl

Links

ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title 1
206010025135 lupus erythematosus Diseases 0.000 title 1
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL12711500T 2011-03-10 2012-03-09 2,4-podstawione pirymidynodiaminy do zastosowania w toczniu krążkowym PL2683385T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161451531P	2011-03-10	2011-03-10
EP12711500.4A EP2683385B1 (en)	2011-03-10	2012-03-09	2,4 substituted pyrimidinediamines for use in discoid lupus
PCT/US2012/028429 WO2012122452A1 (en)	2011-03-10	2012-03-09	2,4 substituted pyrimidinediamines for use in discoid lupus

Publications (1)

Publication Number	Publication Date
PL2683385T3 true PL2683385T3 (pl)	2018-12-31

Family

ID=45922810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12711500T PL2683385T3 (pl)	2011-03-10	2012-03-09	2,4-podstawione pirymidynodiaminy do zastosowania w toczniu krążkowym

Country Status (22)

Country	Link
US (2)	US8497279B2 (pl)
EP (1)	EP2683385B1 (pl)
JP (1)	JP6121917B2 (pl)
KR (1)	KR101802011B1 (pl)
CN (1)	CN103533938A (pl)
AU (1)	AU2012225367B2 (pl)
BR (1)	BR112013023052A2 (pl)
CA (1)	CA2866460C (pl)
CY (1)	CY1120860T1 (pl)
DK (1)	DK2683385T3 (pl)
EA (1)	EA030249B1 (pl)
ES (1)	ES2686532T3 (pl)
HR (1)	HRP20181286T1 (pl)
HU (1)	HUE039486T2 (pl)
LT (1)	LT2683385T (pl)
MX (1)	MX343517B (pl)
PL (1)	PL2683385T3 (pl)
PT (1)	PT2683385T (pl)
RS (1)	RS57672B1 (pl)
SI (1)	SI2683385T1 (pl)
SM (1)	SMT201800456T1 (pl)
WO (1)	WO2012122452A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2857189A1 (en) *	2011-12-08	2013-06-13	Rigel Pharmaceuticals, Inc.	Topical formulation for administering a compound
JP2015528501A (ja)	2012-09-12	2015-09-28	ライジェルファーマシューティカルズ，インコーポレイテッド	白斑の治療法
CN107805212B (zh) *	2017-11-03	2021-08-20	宿迁德威化工股份有限公司	一种2-甲基-5-氨基苯磺酰胺的制备方法
WO2021113410A1 (en) *	2019-12-02	2021-06-10	Ampersand Biopharmaceuticals, Inc.	Transdermal penetrant formulations for vitamins, minerals and supplements
JP2024509309A (ja) *	2021-03-09	2024-02-29	石薬集団中奇制薬技術（石家庄）有限公司	三環式ヘテロアリール基を有する化合物の用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US296006A (en)		1884-04-01		John hoefleb
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
JPS6069037A (ja)	1983-09-26	1985-04-19	Sunstar Inc	エリテマト−デス治療用外用剤
US5008110A (en)	1988-11-10	1991-04-16	The Procter & Gamble Company	Storage-stable transdermal patch
US6010715A (en)	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it)	1993-09-02	1996-06-03	Avantgarde Spa	Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
US5965154A (en)	1998-03-17	1999-10-12	Plc Holding, L.L.C.	Adhesive matrix type transdermal patch and method of manufacturing same
HRP20050089B1 (hr)	2002-07-29	2015-06-19	Rigel Pharmaceuticals	Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
BRPI0610876B8 (pt) *	2005-06-08	2021-05-25	Rigel Pharmaceuticals Inc	composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1948686A4 (en)	2005-10-26	2009-06-10	Stc Unm	C-REACTIVE PROTEIN AND ITS USE FOR THE TREATMENT OF SYSTEMIC LUPUSERYTHEMATODES AND RELATED SUFFERINGS
WO2007070872A1 (en)	2005-12-15	2007-06-21	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses

2012
- 2012-03-09 US US13/416,748 patent/US8497279B2/en not_active Expired - Fee Related
- 2012-03-09 EA EA201391304A patent/EA030249B1/ru not_active IP Right Cessation
- 2012-03-09 HR HRP20181286TT patent/HRP20181286T1/hr unknown
- 2012-03-09 LT LTEP12711500.4T patent/LT2683385T/lt unknown
- 2012-03-09 BR BR112013023052A patent/BR112013023052A2/pt not_active Application Discontinuation
- 2012-03-09 JP JP2013557894A patent/JP6121917B2/ja not_active Expired - Fee Related
- 2012-03-09 SI SI201231361T patent/SI2683385T1/sl unknown
- 2012-03-09 DK DK12711500.4T patent/DK2683385T3/en active
- 2012-03-09 CN CN201280021346.9A patent/CN103533938A/zh active Pending
- 2012-03-09 RS RS20181046A patent/RS57672B1/sr unknown
- 2012-03-09 MX MX2013010308A patent/MX343517B/es active IP Right Grant
- 2012-03-09 PL PL12711500T patent/PL2683385T3/pl unknown
- 2012-03-09 SM SM20180456T patent/SMT201800456T1/it unknown
- 2012-03-09 AU AU2012225367A patent/AU2012225367B2/en not_active Ceased
- 2012-03-09 EP EP12711500.4A patent/EP2683385B1/en active Active
- 2012-03-09 HU HUE12711500A patent/HUE039486T2/hu unknown
- 2012-03-09 PT PT12711500T patent/PT2683385T/pt unknown
- 2012-03-09 WO PCT/US2012/028429 patent/WO2012122452A1/en not_active Ceased
- 2012-03-09 ES ES12711500.4T patent/ES2686532T3/es active Active
- 2012-03-09 CA CA2866460A patent/CA2866460C/en not_active Expired - Fee Related
- 2012-03-09 KR KR1020137026550A patent/KR101802011B1/ko not_active Expired - Fee Related
2013
- 2013-05-30 US US13/906,083 patent/US20130274277A1/en not_active Abandoned
2018
- 2018-09-06 CY CY181100935T patent/CY1120860T1/el unknown

Also Published As

Publication number	Publication date
CN103533938A (zh)	2014-01-22
US8497279B2 (en)	2013-07-30
EP2683385A1 (en)	2014-01-15
US20120232106A1 (en)	2012-09-13
CY1120860T1 (el)	2019-12-11
EP2683385B1 (en)	2018-06-06
RS57672B1 (sr)	2018-11-30
DK2683385T3 (en)	2018-09-17
KR20140025377A (ko)	2014-03-04
AU2012225367B2 (en)	2017-05-25
SI2683385T1 (sl)	2018-11-30
MX343517B (es)	2016-11-07
EA201391304A1 (ru)	2014-05-30
AU2012225367A1 (en)	2013-10-24
US20130274277A1 (en)	2013-10-17
LT2683385T (lt)	2018-10-25
HRP20181286T1 (hr)	2018-10-05
JP6121917B2 (ja)	2017-04-26
ES2686532T3 (es)	2018-10-18
JP2014507480A (ja)	2014-03-27
EA030249B1 (ru)	2018-07-31
WO2012122452A1 (en)	2012-09-13
CA2866460A1 (en)	2012-09-13
CA2866460C (en)	2021-03-09
SMT201800456T1 (it)	2018-11-09
HUE039486T2 (hu)	2019-01-28
PT2683385T (pt)	2018-10-19
KR101802011B1 (ko)	2017-11-27
MX2013010308A (es)	2013-12-02
BR112013023052A2 (pt)	2017-07-25

Publication	Publication Date	Title
GB201112931D0 (en)	2011-09-14	Metail 3
TWM432515U (en)	2012-07-01	M1010701_3919
PL3701800T3 (pl)	2023-10-02	Zastosowanie
ZA201306229B (en)	2014-11-26	Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines
PT2683385T (pt)	2018-10-19	Pirimidinadiaminas 2,4-substituídas para utilização no lúpus discoide
EP2663515A4 (en)	2014-08-20	SPINDLE
TWM432503U (en)	2012-07-01	M1010701_3919
GB201102289D0 (en)	2011-03-23	New use
TWM432266U (en)	2012-07-01	M1010701_3919
TWM432600U (en)	2012-07-01	M1010701_3919
AU5074P (en)	2015-08-13	Crackerjack 2 xTriticosecale
GB201116006D0 (en)	2011-10-26	The time machine
GB201117600D0 (en)	2011-11-23	The squat bar
GB201118453D0 (en)	2011-12-07	Privet portable loo.
GB201104923D0 (en)	2011-05-04	The easy bag
GB201102292D0 (en)	2011-03-23	New use
GB201119436D0 (en)	2011-12-21	Use
GB201107224D0 (en)	2011-06-15	Thermosensitive dressing
GB201108947D0 (en)	2011-07-13	Novel use
GB201103770D0 (en)	2011-04-20	Novel use
GB201102625D0 (en)	2011-03-30	Corcost 888
GB201119739D0 (en)	2011-12-28	Corcost 5863
GB201113285D0 (en)	2011-09-14	Corcost 222244
GB201114541D0 (en)	2011-10-05	Pakaging 27
TWM432344U (en)	2012-07-01	M1010701_3919